tiprankstipranks
ACADIA Pharmaceuticals (DE:DR6)
FRANKFURT:DR6
Germany Market
DR6
ACADIA Pharmaceuticals
RESEARCH TOOLSreports

ACADIA Pharmaceuticals (DR6) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

DR6 Analyst Ratings

Moderate Buy
15Ratings
Moderate Buy
11 Buy
4 Hold
0 Sell
Based on 15 analysts giving stock ratings to
ACADIA
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

DR6 Stock 12 Month Forecast

Average Price Target

€28.94
▲(31.05% Upside)
Based on 15 Wall Street analysts offering 12 month price targets for ACADIA Pharmaceuticals in the last 3 months. The average price target is €28.94 with a high forecast of €33.18 and a low forecast of €20.08. The average price target represents a 31.05% change from the last price of €22.08.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"17":"€17","34":"€34","21.25":"€21.3","25.5":"€25.5","29.75":"€29.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":33.17667558,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€33.18</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":28.936047874285716,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€28.94</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20.08061943,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€20.08</span>\n  </div></div>","useHTML":true}}],"tickPositions":[17,21.25,25.5,29.75,34],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.94,22.804359660000003,23.66871932,24.533078980000003,25.39743864,26.261798300000002,27.12615796,27.990517620000002,28.85487728,29.719236940000002,30.5835966,31.44795626,32.31231592,{"y":33.17667558,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.94,22.47815752879121,23.016315057582418,23.554472586373628,24.092630115164837,24.630787643956047,25.168945172747254,25.707102701538464,26.24526023032967,26.78341775912088,27.32157528791209,27.8597328167033,28.397890345494506,{"y":28.936047874285716,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.94,21.796970725384618,21.65394145076923,21.510912176153848,21.36788290153846,21.22485362692308,21.08182435230769,20.93879507769231,20.79576580307692,20.65273652846154,20.509707253846152,20.36667797923077,20.223648704615385,{"y":20.08061943,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":18.14,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.4,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.01,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.88,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.88,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.88,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.88,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.72,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.45,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.18,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.815,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.515,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.94,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€33.18Average Price Target€28.94Lowest Price Target€20.08
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on DE:DR6
Ananda Ghosh
H.C. Wainwright
H.C. Wainwright
€23.57→€32.3
Buy
46.30%
Upside
Reiterated
07/30/26
Analysts Offer Insights on Healthcare Companies: Cytokinetics (NASDAQ: CYTK), RenovoRx (NASDAQ: RNXT) and ACADIA Pharmaceuticals (NASDAQ: ACAD)
Stifel Nicolaus Analyst forecast on DE:DR6
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
€20.95→€21.83
Hold
-1.15%
Downside
Reiterated
07/25/26
ACADIA Pharmaceuticals (ACAD) Receives a Hold from Stifel Nicolaus
BMO Capital Analyst forecast on DE:DR6
Evan Seigerman
BMO Capital
BMO Capital
€29.68→€31.43
Buy
42.35%
Upside
Reiterated
07/21/26
Analysts Are Bullish on These Healthcare Stocks: Dyne Therapeutics (DYN), ACADIA Pharmaceuticals (ACAD)
Mizuho Securities Analyst forecast on DE:DR6
Uy Ear
Mizuho Securities
Mizuho Securities
€30.56
Buy
38.39%
Upside
Reiterated
07/20/26
Mizuho Securities Sticks to Its Buy Rating for ACADIA Pharmaceuticals (ACAD)
Bank of America Securities Analyst forecast on DE:DR6
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
€26.19
Buy
18.62%
Upside
Reiterated
07/15/26
Bank of America Securities Sticks to Its Buy Rating for ACADIA Pharmaceuticals (ACAD)
RBC Capital Analyst forecast on DE:DR6
Brian Abrahams
RBC Capital
RBC Capital
€25.32→€31.43
Buy
42.35%
Upside
Reiterated
07/07/26
Acadia Pharmaceuticals price target raised to $36 from $29 at RBC CapitalAcadia Pharmaceuticals price target raised to $36 from $29 at RBC Capital
Deutsche Bank Analyst forecast on DE:DR6
David Hoang
Deutsche Bank
Deutsche Bank
€27.94→€32.3
Buy
46.30%
Upside
Reiterated
06/29/26
Acadia Pharmaceuticals price target raised to $37 from $32 at Deutsche BankAcadia Pharmaceuticals price target raised to $37 from $32 at Deutsche Bank
Canaccord Genuity Analyst forecast on DE:DR6
Sumant Kulkarni
Canaccord Genuity
Canaccord Genuity
€27.94→€31.43
Buy
42.35%
Upside
Reiterated
06/29/26
Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (NASDAQ: ACAD), Elanco Animal Health (NYSE: ELAN) and Bristol-Myers Squibb (NYSE: BMY)
TD Cowen Analyst forecast on DE:DR6
Ritu Baral
TD Cowen
TD Cowen
€32.3
Buy
46.30%
Upside
Reiterated
06/26/26
Buy Rating Reiterated on ACADIA as EU Rett Prospects Strengthen; $37 Price Target Unchanged
Morgan Stanley Analyst forecast on DE:DR6
Sean Laaman
Morgan Stanley
Morgan Stanley
€22.7
Hold
2.81%
Upside
Reiterated
06/26/26
Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (NASDAQ: ACAD) and Insmed (NASDAQ: INSM)
Citi Analyst forecast on DE:DR6
Yigal Nochomovitz
Citi
Citi
€30.56
Buy
38.39%
Upside
Assigned
06/26/26
Acadia Pharmaceuticals price target raised to $35 from $32 at CitiAcadia Pharmaceuticals price target raised to $35 from $32 at Citi
Oppenheimer Analyst forecast on DE:DR6
Matthew Hershenhorn
Oppenheimer
Oppenheimer
€20.08
Hold
-9.06%
Downside
Reiterated
05/22/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Cardiff Oncology (NASDAQ: CRDF), ACADIA Pharmaceuticals (NASDAQ: ACAD) and Immunic (NASDAQ: IMUX)
Guggenheim Analyst forecast on DE:DR6
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
―
Hold
―
Reiterated
05/07/26
Guggenheim Keeps Their Hold Rating on ACADIA Pharmaceuticals (ACAD)
Needham Analyst forecast on DE:DR6
Ami Fadia
Needham
Needham
€34.92→€33.18
Buy
50.26%
Upside
Reiterated
05/07/26
Analysts Offer Insights on Healthcare Companies: Kissei Pharmaceutical Co (Other OTC: KSPHF), Recursion Pharmaceuticals (NASDAQ: RXRX) and ACADIA Pharmaceuticals (NASDAQ: ACAD)
Wolfe Research Analyst forecast on DE:DR6
Rudy Li
Wolfe Research
Wolfe Research
€28.81
Buy
30.49%
Upside
Reiterated
05/06/26
ACADIA Pharmaceuticals (ACAD) Gets a Buy from Wolfe Research
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on DE:DR6
Ananda Ghosh
H.C. Wainwright
H.C. Wainwright
€23.57→€32.3
Buy
46.30%
Upside
Reiterated
07/30/26
Analysts Offer Insights on Healthcare Companies: Cytokinetics (NASDAQ: CYTK), RenovoRx (NASDAQ: RNXT) and ACADIA Pharmaceuticals (NASDAQ: ACAD)
Stifel Nicolaus Analyst forecast on DE:DR6
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
€20.95→€21.83
Hold
-1.15%
Downside
Reiterated
07/25/26
ACADIA Pharmaceuticals (ACAD) Receives a Hold from Stifel Nicolaus
BMO Capital Analyst forecast on DE:DR6
Evan Seigerman
BMO Capital
BMO Capital
€29.68→€31.43
Buy
42.35%
Upside
Reiterated
07/21/26
Analysts Are Bullish on These Healthcare Stocks: Dyne Therapeutics (DYN), ACADIA Pharmaceuticals (ACAD)
Mizuho Securities Analyst forecast on DE:DR6
Uy Ear
Mizuho Securities
Mizuho Securities
€30.56
Buy
38.39%
Upside
Reiterated
07/20/26
Mizuho Securities Sticks to Its Buy Rating for ACADIA Pharmaceuticals (ACAD)
Bank of America Securities Analyst forecast on DE:DR6
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
€26.19
Buy
18.62%
Upside
Reiterated
07/15/26
Bank of America Securities Sticks to Its Buy Rating for ACADIA Pharmaceuticals (ACAD)
RBC Capital Analyst forecast on DE:DR6
Brian Abrahams
RBC Capital
RBC Capital
€25.32→€31.43
Buy
42.35%
Upside
Reiterated
07/07/26
Acadia Pharmaceuticals price target raised to $36 from $29 at RBC CapitalAcadia Pharmaceuticals price target raised to $36 from $29 at RBC Capital
Deutsche Bank Analyst forecast on DE:DR6
David Hoang
Deutsche Bank
Deutsche Bank
€27.94→€32.3
Buy
46.30%
Upside
Reiterated
06/29/26
Acadia Pharmaceuticals price target raised to $37 from $32 at Deutsche BankAcadia Pharmaceuticals price target raised to $37 from $32 at Deutsche Bank
Canaccord Genuity Analyst forecast on DE:DR6
Sumant Kulkarni
Canaccord Genuity
Canaccord Genuity
€27.94→€31.43
Buy
42.35%
Upside
Reiterated
06/29/26
Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (NASDAQ: ACAD), Elanco Animal Health (NYSE: ELAN) and Bristol-Myers Squibb (NYSE: BMY)
TD Cowen Analyst forecast on DE:DR6
Ritu Baral
TD Cowen
TD Cowen
€32.3
Buy
46.30%
Upside
Reiterated
06/26/26
Buy Rating Reiterated on ACADIA as EU Rett Prospects Strengthen; $37 Price Target Unchanged
Morgan Stanley Analyst forecast on DE:DR6
Sean Laaman
Morgan Stanley
Morgan Stanley
€22.7
Hold
2.81%
Upside
Reiterated
06/26/26
Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (NASDAQ: ACAD) and Insmed (NASDAQ: INSM)
Citi Analyst forecast on DE:DR6
Yigal Nochomovitz
Citi
Citi
€30.56
Buy
38.39%
Upside
Assigned
06/26/26
Acadia Pharmaceuticals price target raised to $35 from $32 at CitiAcadia Pharmaceuticals price target raised to $35 from $32 at Citi
Oppenheimer Analyst forecast on DE:DR6
Matthew Hershenhorn
Oppenheimer
Oppenheimer
€20.08
Hold
-9.06%
Downside
Reiterated
05/22/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Cardiff Oncology (NASDAQ: CRDF), ACADIA Pharmaceuticals (NASDAQ: ACAD) and Immunic (NASDAQ: IMUX)
Guggenheim Analyst forecast on DE:DR6
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
―
Hold
―
Reiterated
05/07/26
Guggenheim Keeps Their Hold Rating on ACADIA Pharmaceuticals (ACAD)
Needham Analyst forecast on DE:DR6
Ami Fadia
Needham
Needham
€34.92→€33.18
Buy
50.26%
Upside
Reiterated
05/07/26
Analysts Offer Insights on Healthcare Companies: Kissei Pharmaceutical Co (Other OTC: KSPHF), Recursion Pharmaceuticals (NASDAQ: RXRX) and ACADIA Pharmaceuticals (NASDAQ: ACAD)
Wolfe Research Analyst forecast on DE:DR6
Rudy Li
Wolfe Research
Wolfe Research
€28.81
Buy
30.49%
Upside
Reiterated
05/06/26
ACADIA Pharmaceuticals (ACAD) Gets a Buy from Wolfe Research
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
MLYSMineralys Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals Inc
ZURAZura Bio
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering ACADIA Pharmaceuticals

3 Months
Tessa RomeroJ.P. Morgan
Success Rate
9/13 ratings generated profit
69%
Average Return
+8.76%
Copying Tessa Romero's trades and holding each position for 3 Months would result in 69.23% of your transactions generating a profit, with an average return of +8.76% per trade.
1 Year
Ami FadiaNeedham
Success Rate
13/17 ratings generated profit
76%
Average Return
+13.83%
Copying Ami Fadia's trades and holding each position for 1 Year would result in 76.47% of your transactions generating a profit, with an average return of +13.83% per trade.
2 Years
Ami FadiaNeedham
Success Rate
16/17 ratings generated profit
94%
Average Return
+28.31%
Copying Ami Fadia's trades and holding each position for 2 Years would result in 94.12% of your transactions generating a profit, with an average return of +28.31% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

DR6 Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
5
4
7
6
6
Buy
18
15
10
13
16
Hold
9
8
4
4
6
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
32
27
21
23
28
In the current month, DR6 has received 22 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. DR6 average Analyst price target in the past 3 months is 28.94.
Each month's total comprises the sum of three months' worth of ratings.

DR6 Financial Forecast

DR6 Earnings Forecast

Next quarter’s earnings estimate for DR6 is €0.05 with a range of -€0.10 to €0.17. The previous quarter’s EPS was €0.02. DR6 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 0.00% of the time in the same period. In the last calendar year DR6 has Performed in-line its overall industry.
Next quarter’s earnings estimate for DR6 is €0.05 with a range of -€0.10 to €0.17. The previous quarter’s EPS was €0.02. DR6 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 0.00% of the time in the same period. In the last calendar year DR6 has Performed in-line its overall industry.

DR6 Sales Forecast

Next quarter’s sales forecast for DR6 is €256.15M with a range of €248.86M to €265.97M. The previous quarter’s sales results were €232.36M. DR6 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 0.00% of the time in the same period. In the last calendar year DR6 has Performed in-line its overall industry.
Next quarter’s sales forecast for DR6 is €256.15M with a range of €248.86M to €265.97M. The previous quarter’s sales results were €232.36M. DR6 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 0.00% of the time in the same period. In the last calendar year DR6 has Performed in-line its overall industry.

DR6 Stock Forecast FAQ

What is DE:DR6’s average 12-month price target, according to analysts?
Based on analyst ratings, ACADIA Pharmaceuticals’s 12-month average price target is 28.94.
    What is DE:DR6’s upside potential, based on the analysts’ average price target?
    ACADIA Pharmaceuticals has 31.05% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ACADIA Pharmaceuticals a Buy, Sell or Hold?
          ACADIA Pharmaceuticals has a consensus rating of Moderate Buy, which is based on 11 buy ratings, 4 hold ratings and 0 sell ratings.
            What is ACADIA Pharmaceuticals’s share price target?
            The average share price target for ACADIA Pharmaceuticals is 28.94. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €33.18 ,and the lowest forecast is €20.08. The average share price target represents 31.05% Increase from the current price of €22.08.
              What do analysts say about ACADIA Pharmaceuticals?
              ACADIA Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 15 Wall Streets Analysts.
                How can I buy shares of ACADIA Pharmaceuticals?
                To buy shares of DE:DR6, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.